Helus Pharma

Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.

The company's drug candidates include psilocybin (HLP001; CYB001), HLP002 (CYB002; discontinued), HLP003 (CYB003; deuterated psilocin), HLP004 (CYB004; deuterated dimethyltryptamine (DMT)), HLP005 (CYB005; deuterated phenethylamine derivative), and HLP006 (CYB006). Another drug that the company has developed is CYB210010 (2C-T-TFM).

As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 (psilocybin) to have reached this late stage of clinical development.

In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. Helus Pharma was originally known as Cybin but changed its name in December 2025.